Search - tctmd.com

Displaying 1 - 20 of 40

Sort: Relevancy | Date

News Daily News

Side Effects of Statins Might Be Overstated: CTT Collaboration

Michael O'Riordan

February 12, 2026

News Opinion CV Team Dispatch

January 2026 Dispatch for the CV Team

L.A. McKeown

January 16, 2026

News Daily News

Inclisiran Gains Indication as Stand-alone Therapy to Reduce LDL Cholesterol

Michael O'Riordan

August 06, 2025

News Daily News

FDA Approves TAVI for Asymptomatic Patients With Severe Aortic Stenosis

Michael O'Riordan

May 01, 2025

News Daily News

Coverage and Use of Impella and Watchman: A Tale of Four Countries

Michael O'Riordan

March 04, 2025

News Daily News

‘Arbitrary’ Hodgepodge of Composite Endpoints Used Across ASCVD Trials

Michael O'Riordan

February 20, 2025

News Daily News

FDA Approves First ‘Near-Complete’ Stabilizer to Treat ATTR Cardiomyopathy

L.A. McKeown

November 25, 2024

News Daily News

Little Pre- and Postmarket Testing for Most Recalled CV Devices

Michael O'Riordan

September 16, 2024

News Opinion CV Team Dispatch

June 2024 Dispatch for the CV Team

L.A. McKeown

June 01, 2024

News Daily News

Bempedoic Acid Gains CV Risk Reduction Indication

Todd Neale

March 22, 2024

News Daily News

Mechanism’s Mojo: ‘Obvious’ CV Therapies More Likely to Be Seen as Effective

Michael O'Riordan

February 23, 2024

News Daily News

FDA Grants Tirzepatide a New Indication for Obesity Management

L.A. McKeown

November 08, 2023

News Daily News

FDA Approves Paradise Renal Denervation System: What Comes Next?

Todd Neale

November 08, 2023

News Daily News

Medical Devices Cleared on Faulty Predicates More Likely to be Recalled

Michael O'Riordan

January 17, 2023

News Daily News

FDA Advisors Recommend Against Approval of Omecamtiv Mecarbil

Michael O'Riordan

December 14, 2022

News Daily News

Most Patient-Reported Outcome Measures in CVD Fall Short

L.A. McKeown

September 23, 2022

News Features

Novel Targets, Gene Edits, and Vaccines: Is a ‘Golden Era’ Dawning for ASCVD?

Michael O'Riordan

August 15, 2022

News Daily News

FDA Approves Empagliflozin for Treatment of HFpEF

Michael O'Riordan

February 24, 2022

News Features

Pricey Inclisiran Is Rolling Out: a ‘Buy-and-Bill’ Model May Smooth Its Path

Michael O'Riordan

January 17, 2022

News Daily News

British Medical Groups Express Concern About Inclisiran Rollout

Michael O'Riordan

December 14, 2021

Advertisement

Side Effects of Statins Might Be Overstated: CTT Collaboration

January 2026 Dispatch for the CV Team

Inclisiran Gains Indication as Stand-alone Therapy to Reduce LDL Cholesterol

FDA Approves TAVI for Asymptomatic Patients With Severe Aortic Stenosis

Coverage and Use of Impella and Watchman: A Tale of Four Countries

‘Arbitrary’ Hodgepodge of Composite Endpoints Used Across ASCVD Trials

FDA Approves First ‘Near-Complete’ Stabilizer to Treat ATTR Cardiomyopathy

Little Pre- and Postmarket Testing for Most Recalled CV Devices

June 2024 Dispatch for the CV Team

Bempedoic Acid Gains CV Risk Reduction Indication

Mechanism’s Mojo: ‘Obvious’ CV Therapies More Likely to Be Seen as Effective

FDA Grants Tirzepatide a New Indication for Obesity Management

FDA Approves Paradise Renal Denervation System: What Comes Next?

Medical Devices Cleared on Faulty Predicates More Likely to be Recalled

FDA Advisors Recommend Against Approval of Omecamtiv Mecarbil

Most Patient-Reported Outcome Measures in CVD Fall Short

Novel Targets, Gene Edits, and Vaccines: Is a ‘Golden Era’ Dawning for ASCVD?

FDA Approves Empagliflozin for Treatment of HFpEF

Pricey Inclisiran Is Rolling Out: a ‘Buy-and-Bill’ Model May Smooth Its Path

British Medical Groups Express Concern About Inclisiran Rollout

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content